Crinetics Pharmaceuticals, Inc.
CRNX
Kedudukan dalam Saham
#2241
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Harga Saham
$84.95
Disegerakkan terakhir: 2026-09-01
Modal Pasaran
$9.00B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
104.35%
Negara
US
Perdagangan Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
EPS untuk Crinetics Pharmaceuticals, Inc. (CRNX)
EPS setakat June 2026 TTM: $-5.05
Menurut laporan kewangan terkini dan harga saham Crinetics Pharmaceuticals, Inc., EPS semasa syarikat (TTM) adalah $-5.05. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-3.69 peningkatan berbanding EPS tahun 2022 iaitu $-3.15.
Sejarah EPS untuk Crinetics Pharmaceuticals, Inc. dari 2016 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
